Research programme: mannose receptor-targeted diagnostic and therapeutic agents - Macrophage Therapeutics

Drug Profile

Research programme: mannose receptor-targeted diagnostic and therapeutic agents - Macrophage Therapeutics

Alternative Names: CD206 receptor-targeted diagnostics - Navidea Biopharmaceuticals; Cy3-Manocept; Cy3-Manocept-doxorubicin; Cy3-tilmanocept; Manocept™-derived diagnostic agents - Navidea Biopharmaceuticals; MT 1000; MT 1001; MT 2000; MT 2001; MT 2002; MT-1002

Latest Information Update: 05 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Navidea Biopharmaceuticals
  • Developer Macrophage Therapeutics; Navidea Biopharmaceuticals; University of California at San Francisco; Unknown
  • Class Diagnostic agents; Small molecules
  • Mechanism of Action Diagnostic imaging enhancers; Mannose receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer; Cardiovascular disorders; CNS disorders; Infections; Kaposi's sarcoma; Non-alcoholic fatty liver disease; Rheumatoid arthritis; Tuberculosis
  • Research Crohn's disease; Inflammatory bowel diseases

Most Recent Events

  • 29 Mar 2017 Early research in Crohn's disease in USA (unspecified route)
  • 29 Mar 2017 Early research in Inflammatory bowel disease in USA (unspecified route)
  • 26 May 2016 Navidea Biopharmaceuticals receives SBIR grant from National Institutes of Health’s (NIH) National Cancer Institute (NCI) for Manocept™-based immunotargeted treatment in Kaposi’s Sarcoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top